Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 22
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Gain Therapeutics Inc
GANX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.19
N/A
Dern. MÀJ: Oct 22, 7:26 AM
$1.19
N/A
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Gain Therapeutics Financials
Gain Therapeutics (GANX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share
Benzinga Newsdesk
PRO
Gain Therapeutics Q1 EPS $(0.13) Beats $(0.14) Estimate
Benzinga Newsdesk
PRO
Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.17) per share from
Benzinga Newsdesk
PRO
Gain Therapeutics Q2 EPS $(0.19) Misses $(0.17) Estimate
Benzinga Newsdesk
PRO
Gain Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 27.27 percent increase over losses of $(0.22) per share from
Benzinga Newsdesk
